Schrödinger (NASDAQ:SDGR) Price Target Lowered to $25.00 at BMO Capital Markets

Schrödinger (NASDAQ:SDGR) had its price objective lowered by BMO Capital Markets from $30.00 to $25.00 in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other analysts have also issued research reports about the company. Leerink Partners began coverage on Schrödinger in a report on Tuesday, July 2nd. They issued an “outperform” rating and a $29.00 target price for the company. KeyCorp dropped their target price on Schrödinger from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Leerink Partnrs upgraded shares of Schrödinger to a “strong-buy” rating in a report on Tuesday, July 2nd. Finally, Morgan Stanley dropped their price objective on shares of Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 21st. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Schrödinger currently has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Schrödinger Stock Performance

NASDAQ SDGR opened at $17.59 on Thursday. Schrödinger has a 1 year low of $16.67 and a 1 year high of $38.00. The business’s fifty day moving average is $19.33 and its two-hundred day moving average is $21.37. The stock has a market capitalization of $1.28 billion, a P/E ratio of -6.56 and a beta of 1.50.

Schrödinger (NASDAQ:SDGR) last announced its earnings results on Wednesday, July 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.11. The business had revenue of $47.33 million during the quarter, compared to the consensus estimate of $40.19 million. Schrödinger had a negative return on equity of 38.38% and a negative net margin of 100.42%. On average, research analysts forecast that Schrödinger will post -2.19 earnings per share for the current year.

Insider Buying and Selling

In other Schrödinger news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total transaction of $27,221.18. Following the transaction, the insider now directly owns 13,469 shares in the company, valued at $239,478.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 8.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Schrödinger

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SDGR. Nisa Investment Advisors LLC boosted its holdings in shares of Schrödinger by 145.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock worth $27,000 after buying an additional 837 shares during the period. GAMMA Investing LLC grew its position in shares of Schrödinger by 49.5% in the second quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after purchasing an additional 703 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Schrödinger by 186.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,127 shares of the company’s stock worth $76,000 after purchasing an additional 1,385 shares during the period. nVerses Capital LLC acquired a new position in shares of Schrödinger during the 2nd quarter worth about $66,000. Finally, Quest Partners LLC lifted its position in shares of Schrödinger by 1,005.6% during the 2nd quarter. Quest Partners LLC now owns 4,555 shares of the company’s stock worth $88,000 after purchasing an additional 4,143 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.